Autolus Therapeutics PLC (AUTL) intrinsic value & 10-year financials
Autolus Therapeutics PLC (AUTL) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 6 fiscal years revenue grew 566.3% a year to $75.4M, with an average return on invested capital of -1.4%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $1.60
- Market cap
- $425.8M
- Revenue (FY2025)
- $75.4M
- Revenue growth (6-yr CAGR)
- 566.3%
- ROIC (10-yr avg)
- -1.4%
- Free cash flow (FY2025)
- -$302.6M
AUTL 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $75.4M | -$287.5M | -$1.08 | -$302.6M | -358.9% | -138.6% |
| FY2024 | $10.1M | -$220.7M | -$0.86 | -$228.3M | -2385.6% | -285.0% |
| FY2023 | $1.7M | -$208.4M | -$1.20 | -$156.6M | -10583.1% | 248.3% |
| FY2022 | — | -$148.8M | -$1.57 | -$123.1M | — | 222.2% |
| FY2021 | — | -$142.1M | -$1.97 | -$126.7M | — | -53.9% |
| FY2020 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Autolus Therapeutics plc revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Autolus Therapeutics plc has historically struggled to out-earn its cost of capital, averaging just -38.1% ROIC.
Autolus Therapeutics plc capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Autolus Therapeutics plc is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-35.87 per share.